Everything below concerns aggregation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
== Research and career == In 2007 Delibegovic returned to the United Kingdom, where she was awarded the Research Councils UK 5-year tenure track fellowship to investigate obesity and ageing at the University of Aberdeen. She was made Professor in Diabetes Physiology in 2015 at the age of 38. The field of her research has focussed on the PTP1B phosphatase, the molecular mechanisms that cause diabetes and what the relationship is between diabetes and Alzheimer's disease. She has demonstrated that PTP1B can be used for targeted treatments, reaching the cells of specific organs without causing any side effects. In 2017 Delibegovic demonstrated a novel pharmaceutical, Trodusquemine, that could be used to treat type 2 diabetes and breast cancer. She went on to show that a single dose of Trodusquemine, the PTP1B inhibitor, could be used to reverse the effects of atherosclerosis. During the COVID-19 pandemic, Delibegovic, in collaboration with an SME Vertebrate Antibodies Ltd and the NHS Grampian, obtained funding from the Scottish Government/ Chief Scientist office to develop a diagnostic test that could support mass screening for coronavirus disease. Her long-term aim was to use artificial intelligence to identify which parts of the severe acute respiratory syndrome coronavirus 2 activated the body's immune system. At the time, other coronavirus disease tests available in the United Kingdom would not support rapid deployment, and several were unreliable. In May 2020, the tests developed by Delibegovic and her team were in development.
==== Rate of intracellular protein degradation ==== Different proteins are degraded at different rates. Abnormal proteins are quickly degraded, whereas the rate of degradation of normal proteins may vary widely depending on their functions. Enzymes at important metabolic control points may be degraded much faster than those enzymes whose activity is largely constant under all physiological conditions. One of the most rapidly degraded proteins is ornithine decarboxylase, which has a half-life of 11 minutes. In contrast, other proteins like actin and myosin have a half-life of a month or more, while, in essence, haemoglobin lasts for the entire life-time of an erythrocyte. The N-end rule may partially determine the half-life of a protein, and proteins with segments rich in proline, glutamic acid, serine, and threonine (the so-called PEST proteins) have short half-life. Other factors suspected to affect degradation rate include the rate deamination of glutamine and asparagine and oxidation of cystein, histidine, and methionine, the absence of stabilizing ligands, the presence of attached carbohydrate or phosphate groups, the presence of free α-amino group, the negative charge of protein, and the flexibility and stability of the protein. Proteins with larger degrees of intrinsic disorder also tend to have short cellular half-life, with disordered segments having been proposed to facilitate efficient initiation of degradation by the proteasome.
== Further reading == Hoffman, D.C., Ghiorso, A., Seaborg, G. T. The transuranium people: the inside story, (2000), 201–229 Morss, L. R., Edelstein, N. M., Fuger, J., The chemistry of the actinide and transactinide element, 3, (2006), 1630–1636 A Guide to the Elements – Revised Edition, Albert Stwertka, (Oxford University Press; 1998) ISBN 0-19-508083-1
== C == C terminus - Can f 1 - cancer - candidate gene - Canonical sequence - cap - cap site - carbon-monoxide dehydrogenase (cytochrome b-561) - carboxyl terminus - carcinoma - carnitine dehydratase - carrier - carveol dehydrogenase - Catalog of MCA Control Patterns - CAT assay - CAT RNA-binding domain - catalase-related immune-responsive domain - CCAAT box - Cd2+-exporting ATPase - cDNA - cDNA clone - cDNA library - CDP-acylglycerol O-arachidonoyltransferase - cell - centimorgan - centromere - chain terminator - channel-conductance-controlling ATPase - chaperone protein - chlordecone reductase - chloroplast protein-transporting ATPase - cholestanetriol 26-monooxygenase - cholesterol 7alpha-monooxygenase - chromosome - chromosomal translocation - chromosome walking - CIROP gene - CIS - cistron - clone (genetics) - clone (noun) - clone (verb) - cloning - CmERG1 - coding sequence - coding strand - codon - codon usage bias - competent - complementary - conformational epitope - congenital - consensus sequence - conservative substitution - conserved - contig - coproporphyrinogen dehydrogenase - cortisone alpha-reductase - cosmid - costunolide synthase - CpG - craniosynostosis - crp domain - Cu2+-exporting ATPase - cyclodeaminase domain - cyclohexanol dehydrogenase - cyclopeptine synthase - cystic fibrosis - cytogenetic map - cytosine -
Sources: en.wikipedia.org
==== Research ==== In 2005, University of Miami researchers, in cooperation with the attorney representing death-row inmates from Virginia, published a research letter in the medical journal The Lancet. The article presented protocol information from Texas, Virginia, and North and South Carolina, which showed that executioners had no anesthesia training, drugs were administered remotely with no monitoring for anesthesia, data were not recorded, and no peer review was done. Their analysis of toxicology reports from Arizona, Georgia, and North and South Carolina showed that postmortem concentrations of thiopental in the blood were lower than that required for surgery in 43 of 49 executed inmates (88%), and that 21 (43%) inmates had concentrations consistent with awareness. This led the authors to conclude that a substantial probability existed that some of the inmates were aware and suffered extreme pain and distress during execution. The authors attributed the risk of unconsciousness among inmates to the lack of training and monitoring in the process but carefully made no recommendations on how to alter the protocol or how to improve the process. Indeed, the authors conclude, "because participation of doctors in protocol design or execution is ethically prohibited, adequate anesthesia cannot be certain. Therefore, to prevent unnecessary cruelty and suffering, cessation and public review of lethal injections is warranted." Paid expert consultants on both sides of the lethal-injection debate have found opportunity to criticize the 2005 Lancet article.
Yeast species like Hanseniaspora uvarum, Metschnikowia pulcherrima, Saccharomyces uvarum, Zygosaccharomyces cidri, Candida pomicole, and Pichia membranifaciens have also been found to produce enzymes linked to generation of spoilage odors.
== Veterinary use == In veterinary medicine, pantoprazole appears to be safe to use in several large animal species. The pharmacokinetics of pantoprazole have been explored in several veterinary species, including calves, alpacas and foals with half lives reported as 2.81, 0.47, and 1.43 hours, respectively. Pantoprazole appears to be eliminated more quickly in goats when compared to calves, with goats having an elimination half-life of less than one hour. Pantoprazole has been demonstrated to increase the 3rd compartment pH in alpacas. It has been shown to be generally safe to use in cattle, sheep and goats. The subcutaneous bioavailability is greater than 100% in calves. In calves intravenous and subcutaneous administration has been shown to significantly elevate abomasal pH.
According to some analysts, India–U.S. relations have been strained over the Obama administration's approach to Pakistan and the handling of the Taliban insurgency in Afghanistan. India's National Security Adviser M. K. Narayanan criticized the Obama administration for linking the Kashmir dispute to the instability in Pakistan and Afghanistan, and said that by doing so, President Obama was "barking up the wrong tree." Foreign Policy in February 2009 also criticized Obama's approach to South Asia, saying that "India can be a part of the solution rather than part of the problem" in South Asia. It also suggested that India take a more proactive role in rebuilding Afghanistan, irrespective of the attitude of the Obama administration. In a clear indication of the growing rift between the two countries, India decided not to accept a US invitation to attend a conference on Afghanistan at the end of February 2009. Bloomberg has also reported that, since the 2008 Mumbai attacks, the public mood in India has been to pressure Pakistan more aggressively to take actions against the culprits behind the terrorist attack, and that this might reflect on the upcoming Indian general elections in May 2009. Consequently, the Obama administration may find itself at odds with India's rigid stance against terrorism. In the early 2010s, India and US governments have differed on a variety of regional issues ranging from America's military relations with Pakistan and India's military relations with Russia to foreign policy disagreements relating to Iran, Sri Lanka, Maldives, Myanmar and Bangladesh.
Hemoglobin is the principal determinant of the color of blood (hemochrome). Each molecule has four heme groups, and their interaction with various molecules alters the exact color. Arterial blood and capillary blood are bright red, as oxygen imparts a strong red color to the heme group. Deoxygenated blood is a darker shade of red; this is present in veins, and can be seen during blood donation and when venous blood samples are taken. This is because the spectrum of light absorbed by hemoglobin differs between the oxygenated and deoxygenated states. Blood in carbon monoxide poisoning is bright red, because carbon monoxide causes the formation of carboxyhemoglobin. In cyanide poisoning, the body cannot use oxygen, so the venous blood remains oxygenated, increasing the redness. There are some conditions affecting the heme groups present in hemoglobin that can make the skin appear blue – a symptom called cyanosis. If the heme is oxidized, methemoglobin, which is more brownish and cannot transport oxygen, is formed. In the rare condition sulfhemoglobinemia, arterial hemoglobin is partially oxygenated, and appears dark red with a bluish hue. Veins close to the surface of the skin appear blue for a variety of reasons. However, the factors that contribute to this alteration of color perception are related to the light-scattering properties of the skin and the processing of visual input by the visual cortex, rather than the actual color of the venous blood. Skinks in the genus Prasinohaema have green blood due to a buildup of the waste product biliverdin.
Sources: en.wikipedia.org
Some vape pens, generally not referred to as "e-cigarettes", contain cannabis derivatives instead of nicotine and tobacco derivatives. Some cannabis pens, known as "dab pens", contain cannabis extracted using butane as solvent ("butane hash oil"). Other vaporizers contain e-liquid made with pure THC, and they generally resemble conventional e-cigarettes. A 2020 study shows that one third of teenagers engaged in conventional, tobacco vaping also engage in THC vaping. KanaVape is an e-cigarette containing cannabidiol (CBD) and no THC. Several companies including Canada's Eagle Energy Vapor are selling caffeine-based e-cigarettes instead of containing nicotine. Some e-cigarettes marketed as being "nicotine-free" have been found to instead contain the nicotine analogue 6-methylnicotine, which is more potent and may be more addictive than nicotine itself. More broadly, vape pens and e-liquids have become increasingly widely used as a delivery mechanism for a wide variety of illicit and designer drugs. These can include stimulants such as methamphetamine and cocaine, opioids such as fentanyl analogs and nitazenes, a wide variety of synthetic cannabinoids as well as semi-synthetic cannabinoids derived from THC, sedatives including benzodiazepines like etizolam as well as etomidate and methaqualone, psychedelics such as NBOMe substituted phenethylamine derivatives, dissociatives such as ketamine, and assorted other compounds.
For example, the internal thoracic artery can be left attached to the subclavian artery while rerouting blood flow to bypass occluded coronary arteries and improve heart circulation. In organ transplantation, in situ is used to describe procedures performed within the donor's body to preserve organ viability. In situ perfusion is a technique employed during organ retrieval to restore blood flow to organs while they remain in their original location. This method minimizes ischemic injury and preserves organ viability for transplantation. In contrast, ex situ machine perfusion involves perfusing the organ outside the donor's body, typically after it has been removed.
==== Jobs ==== Since the invention of the wheel, technologies have helped increase humans' economic output. Past automation has both substituted and complemented labor; machines replaced humans at some lower-paying jobs (for example, in agriculture), but this was compensated by the creation of new, higher-paying jobs. Studies have found that computers did not create significant net technological unemployment. Due to artificial intelligence being far more capable than computers, and still being in its infancy, it is not known whether it will follow the same trend; the question has been debated at length among economists and policymakers. A 2017 survey found no clear consensus among economists on whether AI would increase long-term unemployment. According to the World Economic Forum's "The Future of Jobs Report 2020", AI is predicted to replace 85 million jobs worldwide and create 97 million new jobs by 2025. From 1990 to 2007, a study in the U.S. by MIT economist Daron Acemoglu showed that an addition of one robot for every 1,000 workers decreased the employment-to-population ratio by 0.2%, or about 3.3 workers, and lowered wages by 0.42%. Concerns about technology replacing human labor, however, are long-lasting. As U.S. President Lyndon Johnson said in 1964 upon signing the National Commission on Technology, Automation, and Economic Progress bill, "Technology is creating both new opportunities and new obligations for us, opportunity for greater productivity and progress; obligation to be sure that no workingman, no family must pay an unjust price for progress."
Although not without conflict, European Canadians' early interactions with First Nations and Inuit populations were relatively peaceful. First Nations and Métis peoples played a critical part in the development of European colonies in Canada, particularly for their role in assisting European coureurs des bois and voyageurs in their explorations of the continent during the North American fur trade. These early European interactions with First Nations would change from friendship and peace treaties to the dispossession of Indigenous lands through treaties. Settler colonialism reached a peak in the late 19th and early 20th centuries. The Canadian government funded Indian residential schools, administered by Christian churches, that are considered to be part of a genocide against Indigenous people due to the institutions' use of forced assimilation. In 2021, possible gravesites of Indigenous children were found near former Canadian residential schools, highlighting the cultural genocide against Indigenous peoples. A period of redress began with the formation of a reconciliation commission by the Government of Canada in 2008. This included acknowledgment of a cultural genocide, settlement agreements, and betterment of racial discrimination issues, such as addressing the plight of missing and murdered Indigenous women.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.